SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Phillip M. Schneider and Randall E. Woods were appointed to its board of directors. Mr. Schneider and Mr. Woods are Arena's seventh and eighth independent directors and bring significant financial and biotechnology industry operations and management experience to Arena's board of directors. Arena's board also appointed Mr. Schneider to its Audit Committee and Mr. Woods to its Corporate Governance and Nominating Committee.
Mr. Schneider is the former Chief Financial Officer of IDEC Pharmaceuticals Corporation. During his 15-year tenure at IDEC, he served as Senior Vice President and Chief Financial Officer, playing an integral role in the company's growth. Prior to his association with IDEC, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation and was previously with KPMG, LLP. Mr. Schneider is a member of the board of directors of Gen-Probe, Inc. and TargeGen, Inc. Mr. Schneider holds an M.B.A. from the University of Southern California and a B.S. in Biochemistry from the University of California, Davis.
Mr. Woods is the President and Chief Executive Officer and a member of
the board of directors of Sequel Pharmaceuticals. Mr. Woods was also
President and Chief Executive Officer of NovaCardia prior to its
acquisition by Merck & Co. Previously, Mr. Woods served approximately eight
years as the Chief Executive Officer of Corvas International, Inc. He was
also President of Boehringer Mannheim's US pharmaceutical operations and
spent approximately 20 years at Eli Lilly & Company in sales and marketing
positions. Mr. Woods currently serves as the chairman for the advisory
board of the Unive
|SOURCE Arena Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved